CRISPR Therapeutics AG Stock News

Big tech stocks cooled off in July, while smaller growth companies rallied. An anticipated rate cut could amplify this trend reversal in August and beyond.

Cathie Wood bought shares of Guardant Health, Oklo, and CRISPR Technologies on Tuesday. Guardant is the only one of the three trading higher this year, fueled by the prospects of a new colorectal cancer screening tool.

Investing guru Cathie Wood still attracts a large following. Although the founder of the Ark Invest family of exchange-traded funds (ETFs) is trailing the market by a wide margin in 2024.

Gene editing stocks represent one of the biggest investing trends in biopharma in recent years. The gene editing field employs advanced technologies to edit the DNA of different organisms, thereby opening up possibilities for transformative treatment options.

CRISPR Therapeutics now has its first product on the market. Zealand Pharma has two promising candidates targeting the huge obesity and MASH/NASH markets.

Gene editing stocks are often biopharmaceutical companies. At these firms, scientists use technology to change the DNA of organisms such as plants, bacteria and animals.

Gene-editing stocks are a promising investment because the field is steadily advancing in the areas of medicine and biotechnology.  Examples include CRISPR and other gene-editing technologies.

Investing in biotech stocks can be rewarding. Not just because these stocks have the potential to produce meaningful gains in your portfolio, but also because when you invest in them, you're investing in companies that are working to treat or heal medical ailments that cause issues for people around the world.